0
Applied AI·October 30, 2026·1 min read

A human subject has been injected with an AI-designed virus aiming to kill antibiotic-resistant bacteria, so let's see how that turns out

Share

An AI-designed virus moving into human trials is a line-crossing moment for bio-AI—therapeutic upside and dual-use risk now coexist in the same workflows. Any organization touching generative biology needs governance, audit trails, and red-team protocols that assume their outputs may eventually enter bodies, not just papers.